Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.
- Published In:
- Molecular pharmaceutics, 10(2), 728-38 (2013)
- Authors:
- Sethi, Varun, Rubinstein, Israel, Kuzmis, Antonina, Kastrissios, Helen, Artwohl, James, Onyuksel, Hayat
- Database ID:
- RPEP-02281
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02281APA
Sethi, Varun; Rubinstein, Israel; Kuzmis, Antonina; Kastrissios, Helen; Artwohl, James; Onyuksel, Hayat. (2013). Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.. Molecular pharmaceutics, 10(2), 728-38. https://doi.org/10.1021/mp300539f
MLA
Sethi, Varun, et al. "Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.." Molecular pharmaceutics, 2013. https://doi.org/10.1021/mp300539f
RethinkPeptides
RethinkPeptides Research Database. "Novel, biocompatible, and disease modifying VIP nanomedicine..." RPEP-02281. Retrieved from https://rethinkpeptides.com/research/sethi-2013-novel-biocompatible-and-disease
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.